Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy

About 70–80% of early breast cancer (BC) patients receive adjuvant endocrine therapy (ET) for at least 5 years. ET includes in the majority of cases the use of aromatase inhibitors, as upfront or switch strategy, that lead to impaired bone health. Given the high incidence and also the high prevalenc...

Full description

Saved in:
Bibliographic Details
Published in:Curr Treat Options Oncol
Main Authors: Diana, Anna, Carlino, Francesca, Giunta, Emilio Francesco, Franzese, Elisena, Guerrera, Luigi Pio, Di Lauro, Vincenzo, Ciardiello, Fortunato, Daniele, Bruno, Orditura, Michele
Format: Artigo
Language:Inglês
Published: Springer US 2021
Subjects:
Breast Cancer (WJ Gradishar, Section Editor)
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8052225/
https://ncbi.nlm.nih.gov/pubmed/33864145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-021-00835-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items